Neuromedin-U Mediates Rapid Activation of Airway Group 2 Innate Lymphoid Cells in Mild Asthma

In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neurom...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 210; no. 6; pp. 755 - 765
Main Authors Ju, Xiaotian, Nagashima, Akimichi, Dvorkin-Gheva, Anna, Wattie, Jennifer, Howie, Karen, Whetstone, Christiane, Ranjbar, Maral, Cusack, Ruth, Ditta, Reina, Paré, Guillaume, Satia, Imran, O’Byrne, Paul M., Gauvreau, Gail M., Sehmi, Roma
Format Journal Article
LanguageEnglish
Published United States American Thoracic Society 15.09.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neuromedin U (NMU), which stimulates type 2 (T2) cytokine secretion by ILC2s, with additive effects to alarmins . To investigate the effect of the NMU/NMUR1 (NMU receptor 1) axis on early activation of ILC2s in asthma. Subjects with mild asthma (  = 8) were enrolled in a diluent-controlled allergen inhalation challenge study. Sputum ILC2 expression of NMUR1 and T2 cytokines was enumerated by flow cytometry, and airway NMU levels were assessed by ELISA. This was compared with samples from subjects with moderate to severe asthma (  = 9). Flow sort-purified and -expanded ILC2s were used for functional assays and transcriptomic analyses. Significant increases in sputum ILC2s expressing NMUR1 were detected 7 hours after allergen versus diluent challenge whereby the majority of NMUR1 ILC2s expressed IL-5/IL-13. Sputum NMUR1 ILC2 counts were significantly greater in mild versus moderate to severe asthma, and NMUR1 ILC2s correlated inversely with the dose of inhaled corticosteroid in the latter group. Coculturing with alarmins upregulated in ILC2s, which was attenuated by dexamethasone. NMU-stimulated T2 cytokine expression by ILC2s, maximal at 6 hours, was abrogated by dexamethasone or specific signaling inhibitors for mitogen-activated protein kinase 1/2 and phosphoinositol 3-kinase but not the IL-33 signaling moiety MyD88 . The NMU/NMUR1 axis stimulates rapid effects on ILC2s and may be an important early activator of these cells in eosinophilic inflammatory responses in asthma.
AbstractList Rationale: In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neuromedin U (NMU), which stimulates type 2 (T2) cytokine secretion by ILC2s, with additive effects to alarmins in vitro. Objectives: To investigate the effect of the NMU/NMUR1 (NMU receptor 1) axis on early activation of ILC2s in asthma. Methods: Subjects with mild asthma (n = 8) were enrolled in a diluent-controlled allergen inhalation challenge study. Sputum ILC2 expression of NMUR1 and T2 cytokines was enumerated by flow cytometry, and airway NMU levels were assessed by ELISA. This was compared with samples from subjects with moderate to severe asthma (n = 9). Flow sort-purified and ex vivo-expanded ILC2s were used for functional assays and transcriptomic analyses. Measurements and Main Results: Significant increases in sputum ILC2s expressing NMUR1 were detected 7 hours after allergen versus diluent challenge whereby the majority of NMUR1+ ILC2s expressed IL-5/IL-13. Sputum NMUR1+ ILC2 counts were significantly greater in mild versus moderate to severe asthma, and NMUR1+ ILC2s correlated inversely with the dose of inhaled corticosteroid in the latter group. Coculturing with alarmins upregulated NMUR1 in ILC2s, which was attenuated by dexamethasone. NMU-stimulated T2 cytokine expression by ILC2s, maximal at 6 hours, was abrogated by dexamethasone or specific signaling inhibitors for mitogen-activated protein kinase 1/2 and phosphoinositol 3-kinase but not the IL-33 signaling moiety MyD88 in vitro. Conclusions: The NMU/NMUR1 axis stimulates rapid effects on ILC2s and may be an important early activator of these cells in eosinophilic inflammatory responses in asthma.Rationale: In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neuromedin U (NMU), which stimulates type 2 (T2) cytokine secretion by ILC2s, with additive effects to alarmins in vitro. Objectives: To investigate the effect of the NMU/NMUR1 (NMU receptor 1) axis on early activation of ILC2s in asthma. Methods: Subjects with mild asthma (n = 8) were enrolled in a diluent-controlled allergen inhalation challenge study. Sputum ILC2 expression of NMUR1 and T2 cytokines was enumerated by flow cytometry, and airway NMU levels were assessed by ELISA. This was compared with samples from subjects with moderate to severe asthma (n = 9). Flow sort-purified and ex vivo-expanded ILC2s were used for functional assays and transcriptomic analyses. Measurements and Main Results: Significant increases in sputum ILC2s expressing NMUR1 were detected 7 hours after allergen versus diluent challenge whereby the majority of NMUR1+ ILC2s expressed IL-5/IL-13. Sputum NMUR1+ ILC2 counts were significantly greater in mild versus moderate to severe asthma, and NMUR1+ ILC2s correlated inversely with the dose of inhaled corticosteroid in the latter group. Coculturing with alarmins upregulated NMUR1 in ILC2s, which was attenuated by dexamethasone. NMU-stimulated T2 cytokine expression by ILC2s, maximal at 6 hours, was abrogated by dexamethasone or specific signaling inhibitors for mitogen-activated protein kinase 1/2 and phosphoinositol 3-kinase but not the IL-33 signaling moiety MyD88 in vitro. Conclusions: The NMU/NMUR1 axis stimulates rapid effects on ILC2s and may be an important early activator of these cells in eosinophilic inflammatory responses in asthma.
In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neuromedin U (NMU), which stimulates type 2 (T2) cytokine secretion by ILC2s, with additive effects to alarmins . To investigate the effect of the NMU/NMUR1 (NMU receptor 1) axis on early activation of ILC2s in asthma. Subjects with mild asthma (  = 8) were enrolled in a diluent-controlled allergen inhalation challenge study. Sputum ILC2 expression of NMUR1 and T2 cytokines was enumerated by flow cytometry, and airway NMU levels were assessed by ELISA. This was compared with samples from subjects with moderate to severe asthma (  = 9). Flow sort-purified and -expanded ILC2s were used for functional assays and transcriptomic analyses. Significant increases in sputum ILC2s expressing NMUR1 were detected 7 hours after allergen versus diluent challenge whereby the majority of NMUR1 ILC2s expressed IL-5/IL-13. Sputum NMUR1 ILC2 counts were significantly greater in mild versus moderate to severe asthma, and NMUR1 ILC2s correlated inversely with the dose of inhaled corticosteroid in the latter group. Coculturing with alarmins upregulated in ILC2s, which was attenuated by dexamethasone. NMU-stimulated T2 cytokine expression by ILC2s, maximal at 6 hours, was abrogated by dexamethasone or specific signaling inhibitors for mitogen-activated protein kinase 1/2 and phosphoinositol 3-kinase but not the IL-33 signaling moiety MyD88 . The NMU/NMUR1 axis stimulates rapid effects on ILC2s and may be an important early activator of these cells in eosinophilic inflammatory responses in asthma.
Rationale: In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host responses at mucosal interfaces. In murine models of asthma, lung ILC2s colocalize to sensory neuronal termini expressing the neuropeptide neuromedin U (NMU), which stimulates type 2 (T2) cytokine secretion by ILC2s, with additive effects to alarmins in vitro. Objectives: To investigate the effect of the NMU/NMUR1 (NMU receptor 1) axis on early activation of ILC2s in asthma. Methods: Subjects with mild asthma (n = 8) were enrolled in a diluent-controlled allergen inhalation challenge study. Sputum ILC2 expression of NMUR1 and T2 cytokines was enumerated by flow cytometry, and airway NMU levels were assessed by ELISA. This was compared with samples from subjects with moderate to severe asthma (n = 9). Flow sort-purified and ex vivo-expanded ILC2s were used for functional assays and transcriptomic analyses. Measurements and Main Results: Significant increases in sputum ILC2s expressing NMUR1 were detected 7 hours after allergen versus diluent challenge whereby the majority of NMUR1+ ILC2s expressed IL-5/IL-13. Sputum NMUR1+ ILC2 counts were significantly greater in mild versus moderate to severe asthma, and NMUR1+ ILC2s correlated inversely with the dose of inhaled corticosteroid in the latter group. Coculturing with alarmins upregulated NMUR1 in ILC2s, which was attenuated by dexamethasone. NMU-stimulated T2 cytokine expression by ILC2s, maximal at 6 hours, was abrogated by dexamethasone or specific signaling inhibitors for mitogen-activated protein kinase 1/2 and phosphoinositol 3-kinase but not the IL-33 signaling moiety MyD88 in vitro. Conclusions: The NMU/NMUR1 axis stimulates rapid effects on ILC2s and may be an important early activator of these cells in eosinophilic inflammatory responses in asthma.
Author Ditta, Reina
Gauvreau, Gail M.
Howie, Karen
Dvorkin-Gheva, Anna
Whetstone, Christiane
Wattie, Jennifer
Nagashima, Akimichi
Ranjbar, Maral
Cusack, Ruth
Sehmi, Roma
O’Byrne, Paul M.
Paré, Guillaume
Satia, Imran
Ju, Xiaotian
Author_xml – sequence: 1
  givenname: Xiaotian
  surname: Ju
  fullname: Ju, Xiaotian
– sequence: 2
  givenname: Akimichi
  surname: Nagashima
  fullname: Nagashima, Akimichi
– sequence: 3
  givenname: Anna
  surname: Dvorkin-Gheva
  fullname: Dvorkin-Gheva, Anna
– sequence: 4
  givenname: Jennifer
  surname: Wattie
  fullname: Wattie, Jennifer
– sequence: 5
  givenname: Karen
  surname: Howie
  fullname: Howie, Karen
– sequence: 6
  givenname: Christiane
  surname: Whetstone
  fullname: Whetstone, Christiane
– sequence: 7
  givenname: Maral
  surname: Ranjbar
  fullname: Ranjbar, Maral
– sequence: 8
  givenname: Ruth
  surname: Cusack
  fullname: Cusack, Ruth
– sequence: 9
  givenname: Reina
  surname: Ditta
  fullname: Ditta, Reina
– sequence: 10
  givenname: Guillaume
  surname: Paré
  fullname: Paré, Guillaume
– sequence: 11
  givenname: Imran
  orcidid: 0000-0003-4206-6000
  surname: Satia
  fullname: Satia, Imran
– sequence: 12
  givenname: Paul M.
  surname: O’Byrne
  fullname: O’Byrne, Paul M.
– sequence: 13
  givenname: Gail M.
  orcidid: 0000-0002-6187-2385
  surname: Gauvreau
  fullname: Gauvreau, Gail M.
– sequence: 14
  givenname: Roma
  orcidid: 0000-0003-0968-6304
  surname: Sehmi
  fullname: Sehmi, Roma
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38598774$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9LxDAQxYOsuLvqF_AgAS9eqvnTNu1xKboKq4IoeJGQpimbpU1q0ir77c1avezB0wwzvzcM783BxFijADjD6ArjNL52UrZXBBGKcUTC4Kk4ADOc0CSKc4YmoUeMRnGcv03B3PsNQphkGB2BKc2SPGMsnoH3RzU426pKm-gVPoQqeuXhs-h0BRey15-i19ZAW8OFdl9iC5fODh0k8N6YgMLVtu3WNsCFahoPtYEPuglS369bcQIOa9F4dfpbj8Hr7c1LcRetnpb3xWIVSZqzPsopqcuyzEQtGc2kSASVtKJ1XiLCqkqiOCxKpVKqAoeTEjNB0qoiSiBFEaXH4HK82zn7MSjf81Z7GR4SRtnB88AwmqeYsIBe7KEbOzgTvuMUo5SlKEnjQJ3_UkMZzOGd061wW_5nXACyEZDOeu9UzaXuf6zqndANx4jvMuK7jPiYER8zClKyJ_27_o_oG4U_lQA
CitedBy_id crossref_primary_10_1016_j_bbcan_2025_189269
crossref_primary_10_3389_fimmu_2024_1430760
crossref_primary_10_1016_j_alit_2025_02_001
crossref_primary_10_1016_j_coi_2024_102501
crossref_primary_10_1097_ACI_0000000000001048
crossref_primary_10_1164_rccm_202404_0844ED
crossref_primary_10_1016_j_coi_2024_102507
crossref_primary_10_1126_scitranslmed_ado6649
Cites_doi 10.1016/j.jaci.2019.01.027
10.1038/s41590-019-0423-0
10.1126/scitranslmed.aar8477
10.3389/fimmu.2023.1130933
10.1111/imm.13257
10.1038/nature12526
10.4049/jimmunol.1300974
10.1038/nature23469
10.1164/rccm.201609-1846OC
10.1183/13993003.02135-2016
10.1038/s41467-019-09883-7
10.1126/science.aan8546
10.1210/en.2010-1463
10.1038/ni.2131
10.1038/s41586-022-05395-5
10.1183/20734735.008914
10.1164/rccm.201612-2427OC
10.1038/ni.2104
10.1164/rccm.201212-2227OC
10.1038/s41385-022-00543-6
10.1111/all.14835
10.1038/nature23676
10.1111/cea.12880
10.1165/rcmb.2022-0123OC
10.1038/nature24029
10.1046/j.1365-2222.1999.00462.x
10.1183/13993003.00536-2015
10.1111/j.1398-9995.2004.00612.x
10.1038/nri.2017.86
10.1373/clinchem.2014.231753
10.1378/chest.123.3_suppl.411S
10.1016/j.jaci.2011.08.031
10.1016/j.jaci.2015.05.037
10.1016/j.jacig.2022.07.007
10.1093/intimm/dxx040
10.1164/ajrccm.154.2.8756799
10.1016/j.immuni.2014.06.016
10.1016/j.jaci.2013.08.023
10.1038/ni.3049
10.1016/j.alit.2022.03.002
10.1159/000107052
10.1164/rccm.201909-1722OC
10.1124/pr.56.2.3
ContentType Journal Article
Copyright Copyright American Thoracic Society Sep 15, 2024
Copyright_xml – notice: Copyright American Thoracic Society Sep 15, 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1164/rccm.202311-2164OC
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
ProQuest Nursing and Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1535-4970
EndPage 765
ExternalDocumentID 38598774
10_1164_rccm_202311_2164OC
Genre Journal Article
GrantInformation_xml – fundername: Mitacs
– fundername: Canadian Lung Association
– fundername: AllerGen
GroupedDBID ---
-~X
.55
0R~
23M
34G
39C
53G
5GY
5RE
7RV
7X7
8C1
8FW
8R4
8R5
AAQQT
AAWTL
AAYXX
ABJNI
ABOCM
ABPMR
ACGFO
ACGFS
ADBBV
AENEX
AFCHL
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BPHCQ
C45
CITATION
CS3
DIK
E3Z
EBS
EJD
EMOBN
EX3
F5P
FRP
GX1
HZ~
IH2
J5H
KQ8
L7B
M5~
O9-
OBH
OFXIZ
OGEVE
OK1
OVD
OVIDX
P2P
PCD
PQQKQ
Q2X
RWL
SJN
TAE
TEORI
THO
TR2
WH7
WOQ
WOW
X7M
YJK
~02
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c397t-932fbbb8afc738ca5a3c3d3f9b027ddc04fc7bee63efbb15b17a26dd2ea0e3033
ISSN 1073-449X
1535-4970
IngestDate Thu Jul 10 20:37:58 EDT 2025
Mon Jun 30 16:29:57 EDT 2025
Thu Apr 03 07:25:05 EDT 2025
Thu Apr 24 23:12:09 EDT 2025
Tue Jul 01 05:40:52 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords allergic asthma
ILC2s
neuro-immune activation
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c397t-932fbbb8afc738ca5a3c3d3f9b027ddc04fc7bee63efbb15b17a26dd2ea0e3033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6187-2385
0000-0003-0968-6304
0000-0003-4206-6000
PMID 38598774
PQID 3106760564
PQPubID 40575
PageCount 11
ParticipantIDs proquest_miscellaneous_3037396127
proquest_journals_3106760564
pubmed_primary_38598774
crossref_citationtrail_10_1164_rccm_202311_2164OC
crossref_primary_10_1164_rccm_202311_2164OC
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-09-15
2024-Sep-15
20240915
PublicationDateYYYYMMDD 2024-09-15
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle American journal of respiratory and critical care medicine
PublicationTitleAlternate Am J Respir Crit Care Med
PublicationYear 2024
Publisher American Thoracic Society
Publisher_xml – name: American Thoracic Society
References Sehmi R (bib30) 2022; 205
bib14
bib36
bib15
bib37
bib12
bib34
bib13
bib35
bib10
bib32
bib11
bib33
bib29
bib27
bib28
bib40
bib25
bib26
bib45
bib24
bib46
bib21
bib43
bib22
Cockcroft DW (bib31) 1987; 135
bib44
bib41
bib20
bib42
bib9
bib7
bib8
bib5
bib18
bib6
bib19
bib3
bib16
bib38
bib4
bib17
bib39
bib1
bib2
Ren X (bib23) 2020; 19
38820208 - Am J Respir Crit Care Med. 2024 Sep 15;210(6):701-703. doi: 10.1164/rccm.202404-0844ED
References_xml – ident: bib14
  doi: 10.1016/j.jaci.2019.01.027
– ident: bib35
  doi: 10.1038/s41590-019-0423-0
– ident: bib19
  doi: 10.1126/scitranslmed.aar8477
– ident: bib26
  doi: 10.3389/fimmu.2023.1130933
– ident: bib43
  doi: 10.1111/imm.13257
– ident: bib45
  doi: 10.1038/nature12526
– ident: bib6
  doi: 10.4049/jimmunol.1300974
– ident: bib39
  doi: 10.1038/nature23469
– ident: bib16
  doi: 10.1164/rccm.201609-1846OC
– ident: bib12
  doi: 10.1183/13993003.02135-2016
– ident: bib36
  doi: 10.1038/s41467-019-09883-7
– volume: 135
  start-page: 264
  year: 1987
  ident: bib31
  publication-title: Am Rev Respir Dis
– ident: bib46
  doi: 10.1126/science.aan8546
– ident: bib41
  doi: 10.1210/en.2010-1463
– ident: bib5
  doi: 10.1038/ni.2131
– ident: bib25
  doi: 10.1038/s41586-022-05395-5
– ident: bib44
  doi: 10.1183/20734735.008914
– ident: bib13
  doi: 10.1164/rccm.201612-2427OC
– ident: bib8
  doi: 10.1038/ni.2104
– ident: bib9
  doi: 10.1164/rccm.201212-2227OC
– ident: bib29
  doi: 10.1038/s41385-022-00543-6
– ident: bib17
  doi: 10.1111/all.14835
– ident: bib40
  doi: 10.1038/nature23676
– ident: bib1
  doi: 10.1111/cea.12880
– ident: bib27
  doi: 10.1165/rcmb.2022-0123OC
– ident: bib28
  doi: 10.1038/nature24029
– ident: bib42
  doi: 10.1046/j.1365-2222.1999.00462.x
– ident: bib2
  doi: 10.1183/13993003.00536-2015
– ident: bib33
  doi: 10.1111/j.1398-9995.2004.00612.x
– ident: bib4
  doi: 10.1038/nri.2017.86
– ident: bib22
  doi: 10.1373/clinchem.2014.231753
– ident: bib32
  doi: 10.1378/chest.123.3_suppl.411S
– ident: bib10
  doi: 10.1016/j.jaci.2011.08.031
– ident: bib11
  doi: 10.1016/j.jaci.2015.05.037
– volume: 205
  start-page: A5011
  year: 2022
  ident: bib30
  publication-title: Am J Respir Crit Care Med
– ident: bib18
  doi: 10.1016/j.jacig.2022.07.007
– ident: bib20
  doi: 10.1093/intimm/dxx040
– volume: 19
  start-page: 809
  year: 2020
  ident: bib23
  publication-title: Exp Ther Med
– ident: bib34
  doi: 10.1164/ajrccm.154.2.8756799
– ident: bib7
  doi: 10.1016/j.immuni.2014.06.016
– ident: bib38
  doi: 10.1016/j.jaci.2013.08.023
– ident: bib3
  doi: 10.1038/ni.3049
– ident: bib21
  doi: 10.1016/j.alit.2022.03.002
– ident: bib37
  doi: 10.1159/000107052
– ident: bib15
  doi: 10.1164/rccm.201909-1722OC
– ident: bib24
  doi: 10.1124/pr.56.2.3
– reference: 38820208 - Am J Respir Crit Care Med. 2024 Sep 15;210(6):701-703. doi: 10.1164/rccm.202404-0844ED
SSID ssj0012810
Score 2.5319052
Snippet In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate rapid host...
Rationale: In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate...
Rationale: In asthma, sputum group 2 innate lymphoid cells (ILC2s) are activated within 7 hours after allergen challenge. Neuroimmune interactions mediate...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 755
SubjectTerms Adult
Airway management
Asthma
Asthma - immunology
Cells
Cytokines
Cytokines - immunology
Cytokines - metabolism
Female
Humans
Immunity, Innate
Lymphocytes - immunology
Lymphocytes - metabolism
Male
Middle Aged
Neuropeptides - metabolism
Receptors, Neurotransmitter
Sputum - immunology
Title Neuromedin-U Mediates Rapid Activation of Airway Group 2 Innate Lymphoid Cells in Mild Asthma
URI https://www.ncbi.nlm.nih.gov/pubmed/38598774
https://www.proquest.com/docview/3106760564
https://www.proquest.com/docview/3037396127
Volume 210
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkKa9IO6UDWQk3qqM-JI4eZwQMA06CbRKfUGR4zhbRJdUXbpp_A3-MMd23IaVIeAlimwnkfx9PT03n4PQ66TUVMmYB0yFLOCsiIJUlyQgvNCpkILQwkR0x8fx4YQfTaPpYPCjl7W0bPN99f2350r-B1UYA1zNKdl_QHb1UhiAe8AXroAwXP8KY1tZw0TH62BiQy5GcRx9kfOqGB0o37jMKpvV4kped64nClKhhqWjT9eAZVMZH-9sZhNjx9UMHr1ozzpx7evT-rhOr9DEohekt4fjfNMEm0x2M2Z_tDRgTivZtD1CHstT08zp3Dl3v1XG81mtdOtL68gPPpzpS7egrtd_ItKHVnx-Tt9_QblJtnAnOPe1l7mRaXQX9oUy7ZJdqw0RK1xZ303RH3PAa6GUqS8AWisJKAy5ypg9LszPLRlYEqWJcA2CbhTc9lN30F0KtocRnh8_r0NTNCGhP30V8zebH9xB2_4Vvyo7t1gwVpM5uY_udSYIPnB8eoAGun6ItscdYI_Q1z6tsKcVtrTCa1rhpsSOVtjSClPsaIU9rbClFa5qbGiFHa0eo8n7dydvD4OuC0egQFdtA1DwyzzPE1kqwRIlI8kUK1iZ5iEVRaFCDhO51jHTsI5EORGSxkVBtQw1KEjsCdqqm1o_Q5jzRCVEhoxqygsWJ6lII5WIkqi8pJIMEfHblamuRL3plDLLrKka88zsduZ2O3O7PUSj1TNzV6Dlj6v3PApZ94u5yJgpowhmfcyH6NVqGsSsiZ3JWjdLWBMywVIwB8QQPXXorT7n0X5-68wu2llTfw9ttYulfgHKbJu_tOT6CVvun9A
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuromedin-U+Mediates+Rapid+Activation+of+Airway+Group+2+Innate+Lymphoid+Cells+in+Mild+Asthma&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Ju%2C+Xiaotian&rft.au=Nagashima%2C+Akimichi&rft.au=Dvorkin-Gheva%2C+Anna&rft.au=Wattie%2C+Jennifer&rft.date=2024-09-15&rft.eissn=1535-4970&rft.volume=210&rft.issue=6&rft.spage=755&rft_id=info:doi/10.1164%2Frccm.202311-2164OC&rft_id=info%3Apmid%2F38598774&rft.externalDocID=38598774
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1073-449X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1073-449X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1073-449X&client=summon